Burzynski Research Institute Past Earnings Performance
Past criteria checks 0/6
Burzynski Research Institute has been growing earnings at an average annual rate of 14.6%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
14.6%
Earnings growth rate
14.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Nov 2023 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses BreakdownBeta
How Burzynski Research Institute makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Nov 23 | 0 | -1 | 0 | 1 |
| 31 Aug 23 | 0 | -1 | 0 | 1 |
| 31 May 23 | 0 | -1 | 0 | 1 |
| 28 Feb 23 | 0 | -1 | 0 | 1 |
| 30 Nov 22 | 0 | -1 | 0 | 1 |
| 31 Aug 22 | 0 | -1 | 0 | 1 |
| 31 May 22 | 0 | -1 | 0 | 1 |
| 28 Feb 22 | 0 | -1 | 0 | 1 |
| 30 Nov 21 | 0 | -1 | 0 | 1 |
| 31 Aug 21 | 0 | -1 | 0 | 1 |
| 31 May 21 | 0 | -1 | 0 | 1 |
| 28 Feb 21 | 0 | -1 | 0 | 1 |
| 30 Nov 20 | 0 | -1 | 0 | 1 |
| 31 Aug 20 | 0 | -2 | 0 | 1 |
| 31 May 20 | 0 | -2 | 0 | 1 |
| 29 Feb 20 | 0 | -2 | 0 | 1 |
| 30 Nov 19 | 0 | -2 | 0 | 1 |
| 31 Aug 19 | 0 | -2 | 0 | 1 |
| 31 May 19 | 0 | -2 | 0 | 1 |
| 28 Feb 19 | 0 | -2 | 0 | 1 |
| 30 Nov 18 | 0 | -2 | 0 | 1 |
| 31 Aug 18 | 0 | -2 | 0 | 1 |
| 31 May 18 | 0 | -2 | 0 | 1 |
| 28 Feb 18 | 0 | -2 | 0 | 1 |
| 30 Nov 17 | 0 | -2 | 0 | 1 |
| 31 Aug 17 | 0 | -2 | 0 | 1 |
| 31 May 17 | 0 | -2 | 0 | 1 |
| 28 Feb 17 | 0 | -2 | 0 | 1 |
| 30 Nov 16 | 0 | -2 | 0 | 1 |
| 31 Aug 16 | 0 | -2 | 0 | 1 |
| 31 May 16 | 0 | -2 | 0 | 2 |
| 29 Feb 16 | 0 | -2 | 0 | 2 |
| 30 Nov 15 | 0 | -2 | 0 | 2 |
| 31 Aug 15 | 0 | -2 | 0 | 2 |
| 31 May 15 | 0 | -3 | 0 | 3 |
| 28 Feb 15 | 0 | -3 | 0 | 3 |
| 30 Nov 14 | 0 | -3 | 0 | 3 |
| 31 Aug 14 | 0 | -3 | 0 | 3 |
| 31 May 14 | 0 | -4 | 0 | 4 |
| 28 Feb 14 | 0 | -4 | 0 | 4 |
| 30 Nov 13 | 0 | -5 | 0 | 5 |
| 31 Aug 13 | 0 | -5 | 0 | 5 |
Quality Earnings: BZYR is currently unprofitable.
Growing Profit Margin: BZYR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BZYR is unprofitable, but has reduced losses over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare BZYR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BZYR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: BZYR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.